yingweiwo

ALK

ALK

Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, is predominantly expressed in the brain and implicated in neuronal development and cognition. Adenosine triphosphate (ATP) and a gamma-phosphate group are transferred via ALK to a tyrosine residue on a substrate protein. As a result, it causes the tyrosine residues in its substrate proteins to phosphorylate. Different enzymes (kinases and phosphatases) catalyze the important protein reactions of phosphorylation and dephosphorylation, which are essential to many cellular processes.

ALK gene activation results from fusion with other oncogenes (NPM, EML4, TIM, etc.) or gene amplification, mutation, or protein overexpression and contributes to the development of several human cancers, including anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors, and neuroblastoma. ALK is a transmembrane tyrosine kinase receptor that dimerizes and then autophosphorylates the intracellular kinase domain in response to ligand binding to its extracellular domain. Specific inhibitors, like Crizotinib, Ceritinib, Alectinib, etc., have shown to be highly effective in treating ALK-positive non-small cell lung cancer in particular when it becomes activated in cancer.

ALK related products

Structure Cat No. Product Name CAS No. Product Description
(E)-Belizatinib V111536 (E)-Belizatinib 1388225-72-6 (E)-Belitazartinib ((E)-TSR-011) (compound 36) is the (E)-isomer of belitazartinib, a potent, selective, and orally effective anaplastic lymphoma kinase (ALK) inhibitor with an enzymatic IC50 of 0.005 μM and a cellular IC50 of 0.048 μM.
ALK C1156Y Recombinant Human Active Protein Kinase V118347 ALK C1156Y Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK degrader 1 V118297 ALK degrader 1 ALK degrader 1 is a highly efficient hydrophobic label-based (HyT) degrader that degrades EML4-ALK (DC50 = 0.13 μM) via the ubiquitin-proteasome system.
ALK degrader 2 V119089 ALK degrader 2 ALK Degrader 2 is an orally effective ALK degrader that degrades EML4-ALK protein (DC50 = 8 nM) and nucleophosphoprotein (NPM)-ALK protein (DC50 = 102 nM).
ALK degrader 3 V128530 ALK degrader 3 ALK degrader 3 is an ALK HyT degrader with an IC50 value of 1.2 nM.
ALK degrader 4 V128531 ALK degrader 4 3111011-76-5 ALK degrader 4 is an ALK HyT degrader with an IC50 value of 0.74 nM.
ALK F1174L Recombinant Human Active Protein Kinase V118883 ALK F1174L Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK F1174S Recombinant Human Active Protein Kinase V119027 ALK F1174S Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK G1202R Recombinant Human Active Protein Kinase V118876 ALK G1202R Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK inhibitor 2 V3324 ALK inhibitor 2 761438-38-4 ALK inhibitor 2 is a novel, potent and selective inhibitor for the ALK kinase (anaplastic lymphoma kinase).
ALK L1196M Recombinant Human Active Protein Kinase V118959 ALK L1196M Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK ligand-1 V119113 ALK ligand-1 2353496-79-2 ALK ligand-1 is an ALK ligand that can be used to synthesize PROTAC ALK degrader-4.
ALK ligand-Linker Conjugate 1 V119290 ALK ligand-Linker Conjugate 1 2796974-34-8 ALK ligand-linker conjugate 1 is an ALK ligand-linker conjugate that can be used to synthesize PROTAC ALK degrader-4.
ALK R1275Q Recombinant Human Active Protein Kinase V118918 ALK R1275Q Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK-IN-12 V69260 ALK-IN-12 1197958-53-4 ALK-IN-12 is a potent and orally bioactive ALK inhibitor (antagonist) with IC50 of 0.18 nM.
ALK-IN-27 V69247 ALK-IN-27 2739866-40-9 ALK-IN-27 (compound 1) is a potent ALK inhibitor.
ALK-IN-33 V110378 ALK-IN-33 ALK-IN-33 (compound 8q) is an orally effective ALK inhibitor with an IC50 value of 1.61 nM.
ALK-IN-34 V128539 ALK-IN-34 ALK-IN-34 is an anaplastic lymphoma kinase (ALK) inhibitor with an IC50 of 0.26 μM.
ALK-IN-37 V128540 ALK-IN-37 ALK-IN-37 is an orally effective type I1/2 allosteric inhibitor that inhibits anaplastic lymphoma kinase (ALK) with an IC50 value of 9.58 nM.
ALK/EGFR-IN-2 V69262 ALK/EGFR-IN-2 2730432-75-2 ALK/EGFR-IN-2 is a potent dual (bifunctional) inhibitor of ALK and EGFR.
Contact Us